Loading clinical trials...
Loading clinical trials...
AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Tigris Pharmaceuticals
NCT07287098 · Breast Neoplasms
NCT07222215 · Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer, and more
NCT07230535 · Breast Cancer, Breast Neoplasms, Breast Reconstruction, and more
NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more
NCT06608446 · Breast Neoplasms
Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions